Atara reports expanded access protocol data of tabelecleucel

Atara Biotherapeutics Inc. (NASDAQ:ATRA) reported data from a U.S. expanded access protocol study showing that IV tabelecleucel led to an objective response rate (ORR)

Read the full 248 word article

User Sign In